Analysts Anticipate MEDNAX, Inc. (NYSE:MD) to Post $0.30 EPS

Equities research analysts forecast that MEDNAX, Inc. (NYSE:MD) will report earnings of $0.30 per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for MEDNAX’s earnings. The highest EPS estimate is $0.33 and the lowest is $0.28. MEDNAX posted earnings of $0.32 per share during the same quarter last year, which would suggest a negative year over year growth rate of 6.3%. The firm is expected to announce its next quarterly earnings report on Thursday, May 6th.

According to Zacks, analysts expect that MEDNAX will report full-year earnings of $1.53 per share for the current year, with EPS estimates ranging from $1.35 to $1.64. For the next financial year, analysts anticipate that the company will post earnings of $1.66 per share, with EPS estimates ranging from $1.51 to $1.81. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow MEDNAX.

MEDNAX (NYSE:MD) last released its earnings results on Thursday, February 18th. The company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.01). MEDNAX had a negative net margin of 26.57% and a positive return on equity of 12.27%.

Several brokerages have recently commented on MD. Deutsche Bank Aktiengesellschaft lifted their target price on MEDNAX from $14.00 to $17.50 and gave the stock a “sell” rating in a research note on Friday. TheStreet upgraded shares of MEDNAX from a “d” rating to a “c-” rating in a research report on Friday, November 13th. Truist increased their target price on MEDNAX from $20.00 to $26.00 in a report on Tuesday, January 5th. Finally, Citigroup decreased their price target on MEDNAX from $24.00 to $22.00 in a research report on Friday. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. MEDNAX presently has an average rating of “Hold” and an average price target of $18.79.

In other news, Director Roger Md Medel sold 66,806 shares of the business’s stock in a transaction that occurred on Wednesday, December 9th. The stock was sold at an average price of $23.00, for a total transaction of $1,536,538.00. Following the transaction, the director now directly owns 1,691,877 shares of the company’s stock, valued at $38,913,171. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.70% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in MD. Alliancebernstein L.P. lifted its position in MEDNAX by 1,340.0% during the fourth quarter. Alliancebernstein L.P. now owns 4,711,026 shares of the company’s stock valued at $115,609,000 after purchasing an additional 4,383,879 shares during the period. BlackRock Inc. grew its position in MEDNAX by 44.2% during the fourth quarter. BlackRock Inc. now owns 12,671,867 shares of the company’s stock valued at $310,968,000 after buying an additional 3,884,888 shares during the period. New York State Common Retirement Fund increased its holdings in MEDNAX by 631.3% during the fourth quarter. New York State Common Retirement Fund now owns 1,586,791 shares of the company’s stock valued at $38,940,000 after buying an additional 1,369,798 shares during the last quarter. Lazard Asset Management LLC raised its stake in shares of MEDNAX by 51.5% in the fourth quarter. Lazard Asset Management LLC now owns 3,489,068 shares of the company’s stock worth $85,621,000 after buying an additional 1,185,912 shares during the period. Finally, Segall Bryant & Hamill LLC lifted its position in shares of MEDNAX by 106.8% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 1,958,336 shares of the company’s stock valued at $31,886,000 after buying an additional 1,011,324 shares in the last quarter. Institutional investors and hedge funds own 95.74% of the company’s stock.

NYSE MD traded up $0.45 during trading on Tuesday, reaching $22.85. 22,848 shares of the company’s stock were exchanged, compared to its average volume of 1,071,117. The company has a debt-to-equity ratio of 2.16, a current ratio of 3.38 and a quick ratio of 3.38. The business has a 50 day moving average price of $25.12 and a 200-day moving average price of $20.39. The stock has a market capitalization of $1.96 billion, a P/E ratio of -2.61, a PEG ratio of 1.70 and a beta of 2.09. MEDNAX has a fifty-two week low of $7.37 and a fifty-two week high of $29.25.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Featured Story: What is the price-to-earnings growth (PEG) ratio?

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.